原发性胆汁性肝硬化发病相关危险因素研究进展*

doi:10.3969/j.issn.1672-5069.2014.01.035

摘要/Abstract

摘要： 原发性胆汁性肝硬化（PBC）是一种原因不明的自身免疫性肝病,多见于中年女性。在已知的诸多发病危险因素中,人口学因素、环境因素和遗传因素以及家族史、吸烟史和尿路感染等一直为人们所重视。近年来,随着研究的深入,特别是全基因组关联研究（GWAS）技术的应用,发现了一些可能导致该病的危险基因,如人类白细胞抗原基因、白细胞介素（IL）-12和X染色体单体等。今后,还需要大量的样本和GWAS数据来验证这一说法,以期从基因水平上阐述该病的发病机制。

关键词: 原发性胆汁性肝硬化, 危险因素, 环境因素, 遗传易感性

Abstract: Primary biliary cirrhosis（PBC） is considered as an idiopathic autoimmune liver disease,mainly found in middle-aged women. Out of many related risk factors,the demographic factors,environmental factors and genetic factors as well as family history,smoking history and urinary tract infections,have always been thought to be important. In recent years,with the progress in basic and clinical research,especially the application of genome-wide association study technology,scholars found some genes,such as human leukocyte antigen genes,interleukin（IL）-12 and the X chromosome monomer,etc,may lead to this disease. In the future,more samples and GWAS data are needed to verify those new findings to elaborate the pathogenesis of the disease in genetic level.

Key words: Primary biliary cirrhosis, Risk factors, Environmental factors, Hereditary susceptibility

李远军综述, 韩者艺, 韩英审校. 原发性胆汁性肝硬化发病相关危险因素研究进展^*[J]. 实用肝脏病杂志, 2014, 17(1): 109-111.

Li Yuanjun, Han Zheyi, Han Ying. Risk factors for the pathogenesis and progression of primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 109-111.

参考文献

[1] Lindor K D,Gershwin M E,Poupon R,et al. Primary biliary cirrhosis. Hepatology,2009,50（1）:291-308.
[2] Smyk D,Rigopoulou E I,Baum H,et al. Autoimmunity and environment:am I at risk. Clin Rev Allergy Immunol,2012,42（2）:199-212.
[3] Lazaridis K N,Juran B D,Boe G M,et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology,2007,46（3）:785-792.
[4] Galbraith R M,Smith M,Mackenzie R M, et al. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med,1974,290（2）:63-69.
[5] Boonstra K,Beuers U,Ponsioen C Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review. J Hepatol,2012,56（5）:1181-1188.
[6] Baldursdottir T R,Bergmann O M,Jonasson J G,et al. The epidemiology and natural history of primary biliary cirrhosis:a nationwide population-based study. Eur J Gastroenterol Hepatol,2012,24（7）:824-830.
[7] Corpechot C,Chretien Y,Chazouilleres O,et al. Demographic, lifestyle,medical and familial factors associated with primary biliary cirrhosis. J Hepatol,2010,53（1）:162-169.
[8] Boone R H,Cheung A M,Girlan L M, et al. Osteoporosis in primary biliary cirrhosis:a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci,2006,51（6）:1103-1112.
[9] Smyk D S,Rigopoulou E I,Muratori L,et al. Smoking as a risk factor for autoimmune liver disease:what we can learn from primary biliary cirrhosis. Ann Hepatol,2012,11（1）:7-14.
[10] Howel D,Fischbacher C M,Bhopal R S,et al. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology,2000,31（5）:1055-1060.
[11] Gershwin M E,Selmi C,Worman H J,et al. Risk factors and comorbidities in primary biliary cirrhosis:a controlled interview-based study of 1032 patients. Hepatology,2005,42（5）:1194-1202.
[12] Ohba K,Omagari K,Kinoshita H,et al. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki,Japan. J Clin Epidemiol,2001,54（8）:845-850.
[13] Kumagi T,Abe M,Ikeda Y,et al. Infection as a risk factor in the pathogenesis of primary biliary cirrhosis: pros and cons. Dis Markers,2010,29（6）:313-321.
[14] Miyakawa H,Tanaka A,Selmi C,et al. Serum reactivity against bacterial pyruvate dehydrogenase:increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis. Clin Dev Immunol,2006,13（2-4）:289-294.
[15] Mattner J,Savage P B,Leung P,et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe,2008,3（5）:304-315.
[16] Van de Water J,Ishibashi H,Coppel R L,et al. Molecular mimicry and primary biliary cirrhosis:premises not promises. Hepatology,2001,33（4）:771-775.
[17] Barzilai O,Sherer Y,Ram M,et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases:are they truly notorious A preliminary report. Ann N Y Acad Sci,2007,1108:567-577.
[18] Bogdanos D P,Baum H,Grasso A,et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol,2004,40（1）:31-39.
[19] Vilagut L,Pares A,Vinas O,et al. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. Eur J Clin Invest,1997,27（8）:667-672.
[20] Bogdanos D P,Pares A,Baum H,et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun,2004,22（4）:353-362.
[21] Taylor-Robinson D,Sharif A W,Dhanjal N S,et al. Chlamydia pneumoniae infection is an unlikely cause of primary biliary cirrhosis. J Hepatol,2005,42（5）:779-780.
[22] Liu H Y,Deng A M,Zhang J,et al. Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis. World J Gastroenterol,2005,11（26）:4108-4110.
[23] Juran B D,Lazaridis K N. Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis,2008,12（2）:349-365.
[24] Jones D E,Watt F E,Metcalf J V,et al. Familial primary biliary cirrhosis reassessed:a geographically-based population study. J Hepatol,1999,30（3）:402-407.
[25] Hirschfield G M,Liu X,Xu C,et al. Primary biliary cirrhosis associated with HLA,IL12A,and IL12RB2 variants. N Engl J Med,2009,360（24）:2544-2555.
[26] Joshita S,Umemura T,Yoshizawa K,et al. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol, 2010,53（3）:537-541.
[27] Juran B D,Lazaridis K N. Update on the genetics and genomics of PBC. J Autoimmun,2010,35（3）:181-187.
[28] Donaldson P T,Baragiotta A,Heneghan M A,et al. HLA class II alleles,genotypes,haplotypes,and amino acids in primary biliary cirrhosis:a large-scale study. Hepatology,2006,44（3）:667-674.
[29] Onishi S,Sakamaki T,Maeda T,et al. DNA typing of HLA class II genes;DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol,1994,21（6）:1053-1060.
[30] Rong G,Zhou Y,Xiong Y,et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis:the serum cytokine profile and peripheral cell population. Clin Exp Immunol,2009,156（2）:217-225.
[31] Lan R Y,Salunga T L,Tsuneyama K,et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun,2009,32（1）:43-51.
[32] Yoshida K,Yang G X,Zhang W,et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology,2009,50（5）:1494-1500.
[33] Schoniger-Hekele M,Muller C,Ackermann J,et al. Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis. Dig Dis Sci,2002,47（9）:1909-1914.
[34] Invernizzi P,Miozzo M,Battezzati P M,et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet,2004,363（9408）:533-535.
[35] Invernizzi P,Miozzo M,Oertelt-Prigione S,et al. X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci, 2007,1110:84-91.

原发性胆汁性肝硬化发病相关危险因素研究进展^*

Risk factors for the pathogenesis and progression of primary biliary cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[2]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[3]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[4]	邱军, 王雪清, 张波, 吕波. 经皮胆道造瘘碎石取石术治疗肝内胆管结石患者疗效分析[J]. 实用肝脏病杂志, 2019, 22(5): 744-747.
[5]	张微, 史军梅, 王倩. 新生儿发生高胆红素血症危险因素分析[J]. 实用肝脏病杂志, 2019, 22(4): 534-536.
[6]	李芳, 邹桂舟, 叶珺, 郜玉峰. 失代偿期肝硬化并发败血症患者临床特征及其危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 557-560.
[7]	刘文博, 张建业, 保积武. ERCP和EST治疗胆总管结石复发危险因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 437-440.
[8]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[9]	王军艳, 陈建婷, 张婷, 范丽, 杜姗, 蒋承志, 牟花妮. 乙型肝炎肝硬化患者院内获得性感染相关危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 101-104.
[10]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[11]	刘映川, 赵鹏程, 游亭, 邓红英, 薛江凤. 熊去氧胆酸联合维生素D治疗PBC患者疗效和外周血T淋巴细胞亚群的变化[J]. 实用肝脏病杂志, 2018, 21(6): 907-910.
[12]	邱婷, 金燕, 吕颐菲, 王雪, 阎春英. 肝硬化并发门静脉血栓危险因素的Logistic回归分析[J]. 实用肝脏病杂志, 2018, 21(6): 916-919.
[13]	严晨丽, 王晶晶, 王军. 非酒精性脂肪性肝病合并冠心病患者冠脉病变程度及其危险因素分析^*[J]. 实用肝脏病杂志, 2018, 21(5): 737-740.
[14]	李福荣, 牛福勇, 李华. 胆管细胞癌组织S100A6 mRNA及其蛋白表达变化^*[J]. 实用肝脏病杂志, 2018, 21(4): 541-544.
[15]	刘进国, 王暴魁. 复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 340-343.